MAS related GPR family member EGenealiases: GPR167 · MGRF · MRGE
Q-omics provides the consensus-scored MRGPRE profile across patient tissues and cancer cell-line models. MRGPRE expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, MRGPRE is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, MRGPRE RNA expression shows 13,138 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight DLBC, HNSC, and THYM as cancer lineages where MRGPRE shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRGPRE — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRGPRE survival associations across molecular data types. MRGPRE RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRGPRE RNA expression–survival associations across cancer types. High MRGPRE expression shows unfavorable associations in DLBC, UVM, UCEC, LIHC and LUSC, but favorable associations in SKCM. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for MRGPRE RNA expression.
This table summarizes MRGPRE tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MRGPRE. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRGPRE shows lower tumor expression in HNSC, COAD, BLCA, LUSC, KICH and UCEC. The HNSC box plot shows higher MRGPRE RNA expression in normal versus tumor tissue (log2 FC = −0.216, t-test p < 0.001).
This table shows molecular features associated with MRGPRE in patient tissues and cancer cell lines. In patient samples, MRGPRE shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MRGPRE RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_SCLC.
